NeuroXess
NeuroXess is a Shanghai-based medical technology company founded in 2021 that develops fully implantable, wireless brain-computer interface systems to restore motor and language function for patients with severe paralysis, ALS, and stroke.
- Company typePrivate
- Founded2021
- HeadquartersHuangpu, China
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuroXess does
NeuroXess (脑虎科技), formally Shanghai Brain Tiger Technology Co., Ltd., is a Shanghai-based life-technology company founded in 2021 that develops implantable flexible brain-computer interface (BCI) systems for medical applications. The company targets patients with severe paralysis from cervical spinal cord injuries, ALS, stroke, and — prospectively — visual impairment, with the goal of restoring motor function and communication through thought-controlled interaction with computers, smart-home devices, wheelchairs, and the patient's own limbs via BCI-FES integration. Its flagship "三全" (Three-Complete: fully implanted, fully wireless, fully functional) system is positioned as China's first and the world's second fully implantable wireless BCI with integrated battery, pairing high-density flexible cortical electrodes (up to 1024 channels, 10μm thickness) placed subdurally with a self-developed 64-channel EEG chip and the proprietary XessOS operating system.
The technology stack is vertically integrated and self-developed end-to-end, including flexible electrode MEMS fabrication, EEG signal acquisition hardware, signal processing and neural decoding algorithms, the XessOS operating system, the XessKey cross-device connectivity component, and surgical robotics. Reported performance metrics include 5.2 BPS motion decoding, 71.5% accuracy on all Mandarin phonemes using pure neural decoding, and full-link latency below 50 milliseconds. As of mid-2026, the company had completed three clinical "三全" implantations (October 2025, December 2025, and follow-on cases) at Huashan Hospital and First Affiliated Hospital of Nanchang University, served over 70 domestic research and medical institutions with BCI research equipment, and conducted more than 50 clinical trials at Huashan Hospital alone.
NeuroXess is pre-revenue and operates an enterprise field-sales GTM through clinical partnerships with top-tier hospitals rather than direct product distribution. The regulatory pathway targets NMPA Class III approval for active implantable medical devices, with the March 2025 creation of a National Medical Insurance BCI reimbursement category covering 1.35 billion potential patients as the eventual commercial tailwind. Manufacturing scale-up is underway through the Jiangxi Ganjiang New Area "Super Factory" (groundbreaking January 2026, expected operational H2 2026, planned 10,000-unit annual capacity) under a "R&D in Shanghai, Production in Jiangxi" dual-core strategy. Capital base includes a 2022 Series A of approximately $15.2M co-led by HSG and Shanda Capital, supplemented by the broader Chinese BCI sector's CNY 4 billion in Q1 2026 and a CNY 11.6 billion government brain science fund launched December 2025.
NeuroXess firmographics
Firmographics- Name
- NeuroXess
- Legal name
- 上海脑虎科技有限公司
- Website
- https://neuroxess.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeuroXess is a Shanghai-based medical technology company founded in 2021 that develops fully implantable, wireless brain-computer interface systems to restore motor and language function for patients with severe paralysis, ALS, and stroke.
- Ownership category
- akta.pro rank
NeuroXess industry classification
Industry- Product category
- Brain-Computer Interface Medical Devices
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical Appliance and Supplies Manufacturing (339113), Semiconductor and Other Electronic Component Manufacturing (3344)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC)
Keywords
Where NeuroXess is headquartered
LocationHeadquarters
- HQ city
- Huangpu
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
NeuroXess business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Implantable BCI Medical Devices: NeuroXess is developing implantable brain-computer interface systems for medical use targeting patients with paralysis, ALS, stroke, and visual impairment. The company has not yet commercialized products as it is in clinical trial stage, but targets regulatory approval through NMPA for Class III active implantable medical devices. Revenue model will likely involve device sales, surgical procedures, and ongoing technical support services.
- Clinical Trial Services & Research Collaborations: The company conducts clinical trials and partners with hospitals and research institutions for technology validation and development. It also serves over 70 domestic research and medical institutions with BCI research equipment.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels10 records
NeuroXess product offering
Product offeringCore offering
NeuroXess develops implantable flexible brain-computer interface (BCI) technology for medical applications. The company focuses on creating flexible, minimally invasive neural electrode arrays and associated signal acquisition and decoding systems to enable patients with neurological conditions to interact with external devices. Products are currently in clinical trial stage and have not yet been commercialized.
Product overview
NeuroXess (脑虎科技) is a life technology company specializing in implantable flexible brain-computer interfaces, founded in 2021. The company has developed a comprehensive product portfolio centered on the '三全' (Full-Implant, Full-Wireless, Full-Function) BCI system - China's first and world's second fully implantable wireless BCI with built-in battery. Supporting products include the proprietary XessOS brain-computer interface operating system, the XessKey cross-device connectivity component, high-density flexible cortical electrodes (up to 1024 channels), self-developed EEG chips, and BCI-FES integration technology. The technology enables real-time motor and language decoding for patients with paralysis, ALS, stroke, and other neurological conditions, with motion decoding at 5.2 BPS and Chinese language decoding at 71.5% accuracy.
Differentiator
Problem solved
Functional benefit
Brands
- XessOS: Proprietary brain-computer interface operating system enabling patients to control computers, browse web, operate smart home devices through thoughts
- XessKey (随芯控)
Products and services
- Implantable Flexible BCI Electrodes Flexible, minimally invasive implantable electrode arrays designed for brain-computer interface applications, intended for use in clinical research and eventual medical treatment of neurological conditions. Targeted at hospitals, neurosurgery departments, and clinical research institutions.
- Neural Signal Acquisition and Decoding System Hardware and software system for acquiring and decoding neural signals from implanted BCI electrodes, enabling patients with neurological conditions to interact with external devices. Targeted at medical research institutions and clinical trial sites.
Quantifiable outcome
- Patient achieved 5.2 BPS (bits per second) brain-controlled cursor performance after 17 days of training, exceeding normal human levels
- +5 more outcomes
Companies that use NeuroXess
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles1 record
NeuroXess technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
NeuroXess partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered supporting, core and flagship.
- External Hardware Manufacturers (for BCI-FES Integration)supportingPartnerships with manufacturers of functional electrical stimulation (FES) equipment and exoskeleton devices for the BCI-FES integrated system that enables patients to control their own limbs through thought.
- Consumer Electronics Ecosystem PartnerssupportingIntegration partnerships with mainstream tablet and computer manufacturers enabling the XessKey cross-device connectivity component to work with standard consumer devices for patient daily use.
- First Affiliated Hospital of Nanchang University (南昌大学第一附属医院)coreRegional clinical trial partner that conducted the second 'Three-Complete' BCI implantation in December 2025 under guidance from Huashan Hospital, expanding clinical trial capacity to central China.
- Huashan Hospital, Fudan University (复旦大学附属华山医院)corePrimary clinical trial partner conducting BCI implant surgeries. Performed China's first fully implantable wireless BCI implantation in October 2025 and multiple subsequent procedures. Provides surgical expertise, patient recruitment, and post-operative care.
- China Ministry of Industry and Information Technology (and six other ministries)flagshipGovernment body that released national BCI development roadmap in August 2025 targeting technological breakthroughs by 2027 and full supply chain by 2030. Provides policy support, regulatory fast-tracks, and funding alignment for BCI industry development.
- Huashan Hospital Chinese Language Decoding Trial PartnershipcoreJoint clinical trial for real-time Chinese language synthesis using high-throughput implantable flexible BCIs, achieving 71% decoding accuracy for 142 common Chinese syllables with sub-100ms latency.
- Jiangxi Provincial Government / Ganjiang New AreaflagshipGovernment partnership for 'Super Factory' manufacturing facility construction. Jiangxi Provincial Government and Ganjiang New Area provide policy support, land, and infrastructure for the 14,300 sqm manufacturing base implementing the 'R&D in Shanghai, Production in Jiangxi' dual-core strategy.
Scale indicators12 records
Recent moves8 records
Expansion highlights7 records
NeuroXess competitors and assessment
Company assessmentDirect peers
- Neuralink: The global leader in implantable brain-computer interfaces, founded by Elon Musk. NeuroXess explicitly benchmarks its motion decoding performance against Neuralink's clinical trial data, and both companies pursue fully implantable, high-channel-count BCI systems targeting paralysis patients.
- BrainCo (强脑科技): Leading Chinese BCI company, also originating from Chinese academic talent pools, focusing on both consumer (education, prosthetics) and medical applications. Closest domestic direct competitor to NeuroXess in the Chinese BCI ecosystem, competing for talent, capital, and government designation.
- Blackrock Neurotech: Pioneer in implantable BCI with decades of clinical research and the most human BCI implantation hours globally. Competes with NeuroXess in the high-channel-count implantable electrode space and serves research institutions — a market overlap with NeuroXess's 70+ research customers.
- Synchron: US-based BCI company developing a minimally invasive, stent-based neural interface. Targets similar paralysis and ALS patient populations as NeuroXess, with multiple completed human implantations and FDA breakthrough designation — competing for the same global BCI market.
Emerging players
- Paradromics: US-based BCI company developing a high-data-rate neural interface with focus on speech restoration and motor control. Targets similar patient populations as NeuroXess with comparable high-channel-count electrode technology.
- Precision Neuroscience: US-based BCI company developing a high-bandwidth, minimally invasive cortical interface. Competes with NeuroXess in the high-channel-count flexible electrode category, with overlapping clinical applications in paralysis and speech restoration.
- Inbrain Neuroelectronics: European BCI company developing graphene-based neural interfaces for neurological and neuropsychiatric disorders. Competes with NeuroXess in the high-resolution implantable electrode space with overlap in clinical applications for motor and language restoration.
Broad incumbents
- Medtronic: Global medical device incumbent with established implantable neurostimulation products (DBS, SCS, VNS, PNS). As a broad neuromodulation incumbent, Medtronic serves as both a competitor for reimbursement budgets and a potential strategic acquirer or distributor for NeuroXess's BCI technology.
- Boston Scientific: Major neuromodulation incumbent with DBS, SCS, and VNS product lines. Competes with NeuroXess for neuroscience clinical budgets and provides benchmark technology and commercial scale for the broader implantable neurotechnology space.
- Abbott: Healthcare incumbent with the Infinity DBS and Proclaim neurostimulation product lines. Represents the established commercial standard for implantable neurotechnology and the most likely strategic acquirer profile for emerging BCI companies like NeuroXess.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NeuroXess social profiles
Digital presenceNeuroXess compliance and trust
Trust signalCompliance2 records
NeuroXess financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroXess leadership team
Management profileNumber of profiles
Profiles2 records
NeuroXess funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroXess M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroXess
What does NeuroXess do?
NeuroXess develops implantable flexible brain-computer interface (BCI) technology for medical applications. The company focuses on creating flexible, minimally invasive neural electrode arrays and associated signal acquisition and decoding systems to enable patients with neurological conditions to interact with external devices. Products are currently in clinical trial stage and have not yet been commercialized.
Is NeuroXess a public or private company?
NeuroXess is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeuroXess founded?
NeuroXess was founded in 2021. It employs 1 to 10 people.
Where is NeuroXess based?
NeuroXess is headquartered in Huangpu, China, in the Asia region.
How does NeuroXess make money?
Two revenue lines are on record. Implantable BCI Medical Devices are the primary driver. The others are clinical Trial Services & Research Collaborations.
Who are NeuroXess's main competitors?
Direct peers on record are Neuralink, BrainCo (强脑科技), Blackrock Neurotech and Synchron. Emerging players are Paradromics, Precision Neuroscience and Inbrain Neuroelectronics. Broad incumbents are Medtronic, Boston Scientific and Abbott.
Does NeuroXess have an API?
No public API is recorded for NeuroXess.
What industry is NeuroXess in?
NeuroXess's product category is Brain-Computer Interface Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HSADAIAC, Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS). Its NAICS code is 33451 and its SIC code is 3845.